Intratumoral IL-2 in patients with stage III melanoma with cutaneous metastasis without lymph node involvement and stage IV melanoma with soft-tissue metastasis without visceral involvement demonstrated unexpected favorable survival rates, and the treatment was associated with increased complete and partial responses in subsequent chemotherapies [24]. Here, IL2 is linked to melanoma.